Back to search results

Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Prostate CA

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • BC Cancer Radiation Oncology, Surrey, British Columbia, Canada

    Contact: Study coordinator (Cathy Tran) · 250 519 5500
    Contact: Study coordinator (Winkle Kwan, MD FRCPC) · wkwan@bccancer.bc.ca · 604 587 4340
    Contact: Principal Investigator (Winkle Kwan, MD FRCPC)
    Anand Karvat, MD FRCPC (Sub-investigator)
    Arthur Cheung, MD FRCPC (Sub-investigator)
    Bernard Lee, MD FRCPC (Sub-investigator)
    Dylan Narinesingh, MD FRCPC (Sub-investigator)
    Jui-Chih Cheng, MD FRCPC (Sub-investigator)
    Ka-Kit David Yeung, MD FRCPC (Sub-investigator)

  • BC Cancer Radiation Oncology, Victoria, British Columbia, Canada

    Contact: Study coordinator (Abraham Alexander) · aalexander3@bccancer.bc.ca
    Contact: Study coordinator (Winkle Kwan) · wkwan@bccancer.bc.ca · 604 587 4340
    Contact: Principal Investigator (Abraham Alexander)
    Sonia Murchison (Sub-investigator)
    Howard Pai (Sub-investigator)
    Jordan Wong (Sub-investigator)
    Saibishkumar Parameswaren (Sub-investigator)
    Abdulla Al-Rashdan (Sub-investigator)
Study leads

  • Abraham Alexander

    Principal Investigator

    BC Cancer

  • Winkle Kwan

    Principal Investigator

    BC Cancer

View source on ClinicalTrials.gov(opens in a new tab)